تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
1.91 US$
+0.04 US$ · +2.14%
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
الإغلاق السابق
1.91 US$
+0.04 US$ · +2.14%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
نطاق اليوم
السعر الحالي 1.91 US$
نطاق 52 أسبوعًا
السعر الحالي 1.91 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
31
مرتفع السعر
المشاعر
48
مختلط
المخاطر
73
مخاطر مرتفعة
الزخم
53
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
نطاق اليوم
السعر الحالي 1.91 US$
نطاق 52 أسبوعًا
السعر الحالي 1.91 US$
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| تكلفة البضاعة المباعة | 1.36 مليون USD | 1.01 مليون USD | 536 ألف USD | — | — |
| الربح الإجمالي | −1.36 مليون USD | −1.01 مليون USD | −536 ألف USD | — | — |
| البحث والتطوير | 59.99 مليون USD | 63.99 مليون USD | 45.49 مليون USD | 23.95 مليون USD | 13.72 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 24.12 مليون USD | 25.21 مليون USD | 21.21 مليون USD | 8.71 مليون USD | 2.47 مليون USD |
| نفقات التشغيل | 82.76 مليون USD | 88.19 مليون USD | 66.7 مليون USD | 32.66 مليون USD | 16.18 مليون USD |
| دخل الفوائد | 6.48 مليون USD | 9.2 مليون USD | 7.04 مليون USD | — | — |
| الاستهلاك والإطفاء | 1.36 مليون USD | 1.01 مليون USD | 536 ألف USD | 364 ألف USD | 37 ألف USD |
| الدخل التشغيلي | −84.11 مليون USD | −89.2 مليون USD | −67.24 مليون USD | −32.66 مليون USD | −16.18 مليون USD |
| صافي الدخل | −77.91 مليون USD | −80.56 مليون USD | −60.39 مليون USD | −31.17 مليون USD | −16.24 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI1.14 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
Vanguard Extended Market ETFVXF814.21 ألف0.00%95.4 مليار USD0.05%235 US$+0.80%
iShares Micro-Cap ETFIWC116.04 ألف0.01%1.32 مليار USD0.60%183 US$+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM110 ألف0.09%116.88 مليون USD0.73%15.9402 US$+0.25%
U.S. Vector Equity Portfolio ETF Class SharesDXUV13.2 ألف0.00%6.18 مليار USD0.26%68.28 US$+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMU.S. Vector Equity Portfolio ETF Class SharesDXUVالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
